ALXO logo

ALXO
Alx Oncology Holdings Inc

1,260
Mkt Cap
$223.73M
Volume
2.6M
52W High
$2.66
52W Low
$0.404
PE Ratio
-0.90
ALXO Fundamentals
Price
$1.70
Prev Close
$1.70
Open
$1.68
50D MA
$2.11
Beta
1.44
Avg. Volume
662,100.69
EPS (Annual)
-$1.90
P/B
3.56
Rev/Employee
$0.00
$30.61
Loading...
Loading...
News
all
press releases
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...
MarketBeat·56m ago
News Placeholder
More News
News Placeholder
ALX Oncology (NASDAQ:ALXO) CEO Sells $26,714.87 in Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $2.17, for a total value of $26,714.87. Following the transaction, the chief...
MarketBeat·19d ago
News Placeholder
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann sold 12,311 shares of the firm's stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an...
MarketBeat·19d ago
News Placeholder
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO)
Wells Fargo & Company initiated coverage on ALX Oncology in a research note on Thursday. They issued an "overweight" rating and a $5.00 target price for the company...
MarketBeat·24d ago
News Placeholder
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Zacks·25d ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are covering the company...
MarketBeat·25d ago
News Placeholder
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
Zacks·26d ago
News Placeholder
IBRX Stock Jumps on Progress in NK Cell Therapy Production
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.
Zacks·27d ago
News Placeholder
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Zacks·27d ago
News Placeholder
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Zacks·30d ago
<
1
2
...
>

Latest ALXO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.